China Pharma Holdings (CPHI) Interest & Investment Income (2010 - 2026)
China Pharma Holdings (CPHI) posted Interest & Investment Income of $147.0 for Q1 2026, down 30.99% on a QoQ basis from $213.0 in Q4 2025, and down 86.31% year-over-year from $1074.0 in Q1 2025.
China Pharma Holdings (CPHI) Interest & Investment Income (2010 - 2026) Analysis & Trends
China Pharma Holdings' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $147.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 86.31% year-over-year to $147.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1076.0 (down 80.07% YoY) and the FY2025 annual result came in at $2003.0, down 69.84% from the prior year.
- Interest & Investment Income was $147.0 for Q1 2026 at China Pharma Holdings, down from $213.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $6655.0 in Q1 2022 and bottomed at $147.0 in Q1 2026.
- A 5-year average of $1538.1 and a median of $1240.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1539.16% — and 2026, when it plunged 86.31%.
- China Pharma Holdings' Interest & Investment Income stood at $1003.0 in 2022, then surged by 152.24% to $2530.0 in 2023, then tumbled by 47.23% to $1335.0 in 2024, then sank by 84.04% to $213.0 in 2025, then sank by 30.99% to $147.0 in 2026.
- Business Quant data shows CPHI's Interest & Investment Income at $147.0 in Q1 2026, $213.0 in Q4 2025, and $294.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 33.15 Mn | 32.99 Mn | 285,487.00 | 147.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.00 |
| Dec 31, 2025 | 213.00 |
| Sep 30, 2025 | 294.00 |
| Jun 30, 2025 | 422.00 |
| Mar 31, 2025 | 1,074.00 |
| Dec 31, 2024 | 1,335.00 |
| Sep 30, 2024 | 1,460.00 |
| Jun 30, 2024 | 1,531.00 |
| Mar 31, 2024 | 2,315.00 |
| Dec 31, 2023 | 2,530.00 |
| Sep 30, 2023 | 2,182.00 |
| Jun 30, 2023 | 942.00 |
| Mar 31, 2023 | 948.00 |
| Dec 31, 2022 | 1,003.00 |
| Sep 30, 2022 | 1,857.00 |
| Jun 30, 2022 | 1,240.00 |
| Mar 31, 2022 | 6,655.00 |
| Dec 31, 2021 | 1,412.00 |
| Sep 30, 2021 | 638.00 |
| Jun 30, 2021 | 579.00 |